Current clinical trial regulations across most Western countries take a similar approach to participants who lack access to healthcare services: they ignore them. These individuals are at increased risk of being exploited by facing the risks and burdens of research without having any chance of sharing in the interventions and treatments that it produces [1]. Yet, new European Union regulations [2] as well as proposed regulations in the U.S. [3] fail to address this concern. In western societies those who lack access to healthcare services tend to be irregular migrants.
